Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype | Synapse

September 9, 2024New England Journal of Medicine137 citations

Ver artículo completo

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

DJDavid J. JacksonGuy's Hospital MWMichael E. WechslerNational Jewish Health DJDaniel J. JacksonUniversity of Wisconsin–Madison

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Jackson et al. (Mon,) studied this question.

synapsesocial.com/papers/68e58fe4b6db64358752b1b6 https://doi.org/https://doi.org/10.1056/nejmoa2406673